OHR 1601

Completed Studies

A Phase III study of Efficacy and Safety of Squalamine Lactate Opthalmic Solution, 0.2% twice daily in subjects with Neovascular AMD.

Duration: 2 years

This entry was posted in Uncategorized. Bookmark the permalink.